Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Deborah_Waterhouse
|
| gptkbp:country |
gptkb:United_Kingdom
|
| gptkbp:focusesOn |
HIV prevention
HIV treatment |
| gptkbp:foundedIn |
2009
|
| gptkbp:headquartersLocation |
gptkb:London
|
| https://www.w3.org/2000/01/rdf-schema#label |
ViiV Healthcare
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:notableProduct |
gptkb:Cabotegravir
gptkb:Dolutegravir gptkb:Dovato gptkb:Juluca gptkb:Triumeq gptkb:Vocabria |
| gptkbp:operatesIn |
global
|
| gptkbp:parentCompany |
gptkb:Pfizer
gptkb:Shionogi GlaxoSmithKline |
| gptkbp:partner |
gptkb:Pfizer
gptkb:Shionogi GlaxoSmithKline |
| gptkbp:specializesIn |
antiretroviral drugs
|
| gptkbp:website |
https://www.viivhealthcare.com/
|
| gptkbp:bfsParent |
gptkb:cabotegravir
gptkb:dolutegravir gptkb:GSK gptkb:Shionogi |
| gptkbp:bfsLayer |
6
|